Transplanting HCV+ kidneys into HCV- recipients feasible

Transplanting HCV+ kidneys into HCV− recipients feasible

(HealthDay)—In a research letter published online April 30 in the New England Journal of Medicine, Philadelphia doctors write that they have cleared hepatitis C infections in 10 patients who received kidneys from deceased donors who had the virus.

In 2016, researchers at Penn Medicine began investigating the effectiveness of transplants from donors with C. The kidneys were given to between 40 and 65 years old who had waited for at least a year and a half. Patients and their families underwent a thorough vetting process, to make sure they understood the risks involved.

After receiving the , all 10 patients tested positive for hepatitis C. All were treated with a 12-week antiviral therapy of elbasvir/grazoprevir. Early data from the study revealed this treatment effectively cleared hepatitis C from all of the patients.

"Our pilot data demonstrate the ability to cure the contracted virus following transplantation in this patient population," study co-leader, David Goldberg, M.D., an assistant professor of and epidemiology at the University of Pennsylvania School of Medicine in Philadelphia, said in a university news release. "If future studies are successful, this may be a viable option for patients who may otherwise never see a transplant."

More information: Abstract/Full Text

Journal information: New England Journal of Medicine

Copyright © 2017 HealthDay. All rights reserved.

Citation: Transplanting HCV+ kidneys into HCV- recipients feasible (2017, May 14) retrieved 22 February 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors


Feedback to editors